EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 311 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR New Study Shows Intermittent Fasting May Reduce Breast Cancer Risk and... January 26, 2021 Catch up on Behind the Science 2021 – From funding stream... May 17, 2021 Survivor Guest Post: Living Breast-less June 18, 2019 Study Tackles Key Questions about Liver Transplants for People with Liver... August 24, 2022 Load more HOT NEWS EMA Recommends Additional Extensions of Indications for Pembrolizumab FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes 8-Year-Old Cancer Survivor Breaks National Record for Girl Scout Cookie Sales FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who...
